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Abstract p63, cytokeratin (CK) 5/6 and CK 14 have been
employed in diagnostic pathology as markers of basal,
squamous and myoepithelial differentiation in several
types of human neoplasms; however, there is scant data
on the concurrent expression of these markers in large
series of human neoplasms. We analyzed the distribution
of these three immunohistochemical markers in 51 normal
human tissue samples, 350 carcinomas, 25 malignant
melanomas (MMs), and 25 glioblastomas using three
serial sections of tissue array research program (TARP)-4
multi-tumor tissue microarray. Also, we performed dou-
ble immunostainings to characterize the differential
distribution of p63/CK 5/6 and p63/CK 14 in normal
breast, salivary gland and skin. p63, CK 5/6 and CK 14
were expressed in basal cells of the prostate and
respiratory epithelia and in breast and bronchial myoepi-
thelial cells. p63 was also expressed in cytotrophoblast
cells of human placenta and in scattered cells of lymph
node germinal center. CK 5/6 and CK 14 also stained the
cytoplasm of basal cells of esophageal stratified squa-
mous epithelium and transitional epithelial cells of the
bladder. No mesenchymal, neural, endothelial, smooth
muscle or adipose cells were stained by any of the
markers. p63, CK 5/6, and CK 14 were respectively
expressed in 92.6%, 75.0%, and 52.9% of the squamous
cell carcinomas of the lung, 10.2%, 20.0%, and 7.4% of
the ductal carcinomas of the breast, 12.9%, 34.4%, and
11.8% of the serous and 25.0%, 0%, and 0% of the
endometrioid carcinomas of the ovary. Lung, prostate and
colonic adenocarcinomas, as well as MMs and glioblas-
tomas were only rarely decorated by one of the markers.
Only matched samples of 16 squamous cell carcinomas
and two ductal carcinomas of the breast co-expressed
these three markers. In double immunostainings, p63-CK
5/6, as well as p63-CK 14 were co-expressed by basal/
myoepithelial cells of the salivary glands and basal cells
of the epidermis. Our results demonstrate that p63, CK 5/
6 and CK 14 may be used together in immunohistochem-
ical panels to characterize squamous differentiation in
poorly differentiated carcinomas or carcinomas of un-
known origin.
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Introduction
Cytokeratin (CK) is one of the three types of intermediate
filaments that constitute the cytoskeleton of epithelial
mammalian cells [7, 26]. At least 20 different keratin
genes located either on chromosome 12 or 17 have been
described [7, 38]. Each of these genes encodes specific
keratin subunits, which may be classified as low- or high-
molecular-weight CKs and as acidic or basic forms, based
on their isoelectric points [7, 26]. Type-I CKs are small,
acidic and encoded by genes located on chromosome 17,
whereas type-II CKs are large, basic, and encoded by
genes on chromosome 12 [7, 26, 38]. In epithelial cells,
keratin filaments are composed of one type-I and one
type-II CK [7, 26]. Different keratin isoforms are
differentially expressed during development and differ-
entiation and vary in different types of epithelia [2, 6, 7, 8,
9, 13, 28, 38, 40, 41, 42]. Several lines of evidence
support that when an epithelial cell undergoes malignant
transformation, it usually harbors a constant keratin
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profile, and this profile might serve to recognize different
types of carcinomas [2, 6, 7, 8, 9, 13, 28, 38, 40].
CK 5 and CK 14, also known as basal-type CKs, are
consistently expressed in basal cells of multilayered
epithelia, myoepithelial cells of the breast, salivary and
sweat glands, Hassall’s corpuscles of the thymus, para-
thyroid glands, hair follicle’s outer root sheath, sebaceous
glands and mesothelial cells [2, 6, 7, 8, 9, 13, 42]. CK 6 is
a type-II CK expressed in filiform papillae of the tongue,
oral and esophageal epithelia, the outer root sheath of the
hair follicle and occasional glandular cells, but not in the
breast [7]. CK 6 is only expressed in the epidermis of the
palms and soles, or when it has undergone hyperplasia
[7].
p63 is a nuclear transcription factor that harbors a high
homology with p53 [10, 22, 32]. Its gene is located on
3q27 and encodes at least six different isoforms that may
be classified in two discrete groups: transactivating p63
(TA-p63) isoforms, which may bind to p53-reporter genes
and activate their transcription and dominant negative p63
(DN-p63) isoforms, which lack the transactivating N-
terminal region and can bind to canonical DNA-binding
sites but cannot transactivate these genes [10, 22, 32]. We
[32, 33, 34, 35, 36, 37] and others [1, 5, 10, 11, 12, 19, 22,
24, 27, 29, 30, 31, 39, 43, 44, 46, 47] have described that
p63 isoforms recognized by the antibody 4A4 are
consistently expressed in the nuclei of basal cells of
several types of multilayered epithelia and that DN-p63
isoforms are preferentially expressed in these cells.
Dominant-negative p63 isoforms play an important role
in the maintenance of basal cell populations, owing to
their ability to overcome p53-driven cell cycle arrest and
apoptosis [11, 19, 22, 24, 32, 47]. p63 is also consistently
expressed by myoepithelial cells of the breast, salivary,
bronchial and sweat glands [1, 5, 10, 11, 12, 19, 22, 24,
27, 30, 31, 32, 33, 34, 35, 36, 37]. Interestingly, p63
knockout mouse models have shown that the expression
of p63 is of utmost importance for the correct differen-
tiation of several types of multilayered epithelia [22, 27,
47] and that p63 may promote the transcription of genes
associated with terminal epithelial differentiation [10, 22,
24, 47].
Multi-tumor tissue microarrays (TMAs) have proven
to be very powerful tools for several purposes, including
prognostic studies using immunohistochemical or in situ
hybridization techniques, as well as the validation of
results obtained from cDNA array experiments [3, 4, 11,
15, 16, 20, 25, 48]. However, there are limited data on
TMAs for the evaluation of the distribution of antibodies
that might be used as diagnostic markers in surgical
pathology practice. As p63, CK 5/6 and CK 14 show a
similar distribution in several types of tissues [2, 6, 8, 9,
11, 13, 19, 24, 28, 32, 33, 34, 35, 37, 38, 43, 47], our goals
were: (i) to describe the expression of p63, CKs 5/6 and
CK 14 in 51 normal tissue samples and in 350 epithelial
neoplasms, 25 melanomas and 25 glioblastomas using
three serial sections of tissue array research program
(TARP)-4 multi-tumor TMA; (ii) to determine which
types of human tumors co-express these markers; and (iii)
to evaluate the impact of these markers in surgical
pathology practice. We also performed double-immunos-
tainings for p63/CKs 5/6 and p63/CK 14 to demonstrate
the concurrent expression of these proteins in normal
mammary and salivary gland myoepithelial cells, as well
as in basal keratinocytes.
Materials and methods
Tissue microarray
TARP-4 multi-tumor TMA slides were obtained from the Coop-
erative Human Tissue Network under the TARP of The National
Cancer Institute, The National Institutes of Health, Bethesda, MD,
USA. Briefly, this multi-tumor TMA is composed of 0.6-mm
samples of normal tissue [n=51: adrenal (n=2), bladder (n=2), bone
marrow (n=1), breast (n=5), cerebellum (n=1), cerebrum (n=2),
colon (n=2), esophagus (n=2), heart (n=1), kidney (1 cortex and 1
medulla), liver (n=3), lung (n=3), lymph node (n=2), mesothelium
(n=2), muscle (n=1), ovary (n=2), pancreas (n=1), peripheral nerve
(n=1), placenta (n=1), prostate (n=2), salivary gland (n=1), skin
(n=2), small bowel (n=2), spleen (n=2), stomach (n=1), testis (n=1),
thyroid (n=1), tongue (n=1), uterus (1 endometrium and 1
myometrium)], breast cancer (n=75), colon cancer (n=75), lung
cancer (n=75), prostate cancer (n=75), ovarian cancer (n=50),
lymphoma (n=50), glioblastoma (n=25), and melanoma (n=25). As
the original TARP-4 database includes only scant data on the
expression of immunomarkers expressed by the lymphomas
included in the TMA block (http://resresources.nci.nih.gov/tarp/
TARP4.xls) and does not include their final diagnosis, we decided
to exclude these cases.
Immunohistochemistry
TMA sections were dried under a low-power ultraviolet light for
120 min. All sections were deparaffinized, rehydrated and subject-
ed to heat-induced antigen retrieval in a water bath, using citrate
buffer at pH 6.0 (CK 14 and p63) and pH 8.0 (CK 5/6) for 20 min.
Immunohistochemistry according to the streptavidin-biotin-perox-
idase complex technique with antibodies against all p63 isoforms
(clone 4A4, 1:200; Neomarkers, Freemount, CA, USA), CK 5/6
(clone D5/16B4, 1:200; Zymed, South San Francisco, CA, USA),
and CK 14 (clone MCA890H, 1:200; Serotec, 1:10, Oxford, UK)
was performed as described elsewhere [37]. Positive (histological
sections of a sclerosing papilloma with myoepithelial hyperplasia
for p63 and skin for CK 5/6 and CK14) and negative (omission of
primary and secondary antibodies) controls were included in each
slide run. All controls gave appropriate results.
The distribution of p63, CK 5/6 and CK 14 was independently
evaluated by two of the authors (JSRF and AM). All discordant
results were resolved in a multi-head microscope. The differential
expression of p63, CK 5/6 and CK 14 in normal tissue samples was
recorded. p63, CK 5/6 and CK 14 expression in neoplastic samples
on the TMA was quantitatively assessed and recorded as: ()
negative; (+) focally positive, up to 25% of neoplastic cells; or (++)
positive, greater than 25% of the neoplastic cells. Briefly, all
neoplastic cells of each TMA core were counted and a ratio
between the number of positive cells 100/number of negative cells
was calculated.
For statistical analysis, cases were recorded either as () or as
(+), without semiquantification of the positive cases.
Double immunostaining
One normal parotid, one minor salivary gland and one normal
breast sample were subjected to double immunostaining, as
described elsewhere [23], using p63 as first primary antibody and
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either CK 5/6 or CK 14 as second primary antibody. Briefly, the
sections were submitted to heat-induced antigen retrieval using a
water bath with 10 mM citrate buffer (pH 6.0) before incubating for
2 h at room temperature with the first primary antibody. Then, the
sections were sequentially incubated with biotin labeled secondary
antibody for 30 min, avidin-biotin-peroxidase complex for 60 min
and DAB for 5 min. Sections were then sequentially incubated with
the second primary antibody for 2 h at room temperature, goat anti-
mouse IgG for 30 min, alkaline phosphatase mouse anti-alkaline
phosphatase for 60 min and fast-red for 45 min. Controls included
(a) omission of the first primary antibody and (b) omission of the
second primary antibody.
Statistical analysis
The statistical associations between the distribution of p63, CK 5/6
and CK 14 in different types of neoplasms were evaluated using the
c2 test. We also evaluated whether matched samples of p63 positive
(+) tumors also co-express CK 5/6 and CK 14 more frequently than
p63 negative () tumors using Fisher’s exact test. For statistical
analysis, only carcinoma samples were evaluated. The ductal
carcinoma in situ (DCIS) sample and the tubular adenoma samples
(n=2) were excluded. All tests were two tailed. A 95% confidence
interval was adopted for all tests.
Results
p63
Normal tissue samples
Table 1 summarizes the distribution of p63 immunoreac-
tivity in normal tissue samples. Briefly, p63 decorated
basal cells of the prostate and of the pseudostratified
respiratory epithelium, myoepithelial cells of the bron-
chial glands and cytotrophoblasts of human placenta
(Fig. 1A). Scattered lymphoid cells in the germinal
centers were also stained with p63. No endothelial,
smooth muscle, neural or adipocytic cells were stained
with anti-p63 antibodies in any of the organs examined
herein.
Neoplasms
In the present study, the distribution of p63 immunore-
activity was analyzed in 400 tumors (Table 2). Concern-
ing carcinomas, p63 was consistently expressed in
squamous cell carcinomas of the lung (92.6%) (Fig. 2A),
Table 1 Summary of p63, CK 5/6 and CK 14 distribution in 51 normal tissue samples using tissue array research program (TARP)-4
multi-tumor tissue microarrays. CK cytokeratin, L/F lost/fragmented, NA not available
Tissue n p63 L/F Note CK
5/6
L/F Note Ck
14
L/F Note
Adrenal 2 - 0 + 0 - 0
Bladder 2 - 0 No epithelial cells + 1 Epithelial cells 1 1 Transitional cells
Bone marrow 1 - 0 NA 1 NA 1
Breast 5 - 2 Only fat cells 1 4 Basal/myoepithelial
cells
+ 4 Basal cells
Cerebellum 1 - 0 - 0 - 0
Cerebrum 2 - 0 - 0 - 0
Colon 2 - 0 - 0 - 0
Esophagus 2 NA 2 No epithelial cells + 1 Epithelial cells NA 2
Heart 1 - 0 NA 1 - 0
Kidney 2 - 0 - 1 - 1
Liver 3 - 0 + 0 Focal - 0
Lung 3 + 0 Basal cells of
respiratory epithelium
+ 0 Basal cells of
respiratory epithelium
+ 2 Basal cells of
respiratory epithelium
Lymph node 2 + 0 Germinal center cells - 0 - 0
Mesothelium 2 - 0 NA 2 No mesothelial cells NA 2 No mesothelial cells
Muscle 1 - 0 - 0 - 0
Ovary 2 - 0 - 0 - 0
Pancreas 1 - 0 + 0 Scattered acinar cells - 0
Peripheral nerve 1 NA 1 - 0 - 0
Placental 1 + 0 Cytotrophoblast cells NA 1 NA 1
Prostate 2 + 0 Basal cells + 0 Basal cells of the acini + 0 Basal cells of the
acini
Salivary gland 1 - 1 Severely fragmented + 0 Basal cells of acini
and intercalated ducts
+ 0 Basal cells of acini
and intercalated ducts
Skin 2 - 0 No keratinocytes NA 2 NA 2
Small bowel 2 - 0 - 0 - 1
Spleen 2 - 0 - 0 - 0
Stomach 1 NA 1 + 0 Parietal cells - 0
Testis 1 - 0 - 0 - 0
Thyroid 1 NA 1 NA 1 NA 1
Tongue 1 NA 1 NA 1 NA 1
Uterus 2 - 1 Rare endometrial cells - 0 - 0
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and was occasionally expressed in ductal carcinomas of
the breast (10.2%) (Fig. 2B), adenocarcinomas (13.8%)
and poorly differentiated carcinomas of the lung (33.3%),
adenocarcinoma of the colon (1.6%), serous (12.9%) and
endometrioid (25.0%) carcinomas of the ovary. Of note,
entrapped ducts and acini with p63 + basal cells amidst
breast and prostate carcinomas were occasionally ob-
served. p63 also stained 10% of primary malignant
melanomas and 12% of glioblastomas.
Fig. 1 A p63 expression in cytotrophoblasts of a placenta tissue
core. B Medium-power magnification of pancreas tissue core: note
the presence of scattered cytokeratin 5/6-positive cells. (Streptavi-
din-biotin-peroxidase/diaminobenzidine; original magnification
200 A, B)
Table 2 Summary of p63, CK 5/6 and CK 14 distribution in 350
carcinomas, 25 malignant melanomas, and 25 glioblastomas using
tissue array research program (TARP)-4 multi-tumor tissue
microarrays. Adenoca adenocarcinoma, CCC clear cell carcinoma,
CK cytokeratin, CNS central nervous system, DCIS ductal carci-
noma in situ, Endomet endometrioid carcinoma, IDC invasive
ductal carcinoma, ILC invasive lobular carcinoma, L/F/N lost/
fragmented/necrotic, Muc adenoca mucinous adenocarcinoma,
N.A. not available, PDC poorly differentiated carcinoma, SCC
squamous cell carcinoma, Serous pap serous papillary carcinoma,
Tub adeno tubular adenoma
Tumor samples n p63
(+)
p63
(++)
L/F/N Total
(%)
CK 5/
6(+)
CK 5/
6(++)
L/F/N Total
(%)
Ck
14(+)
Ck
14(++)
L/F/
N
Total
(%)
Breast 75 5 1 7 8.8 11 3 12 22.2 3 2 13 8.1
IDC 65 5 1 6 10.2 8 3 10 20.0 2 2 11 7.4
ILC 9 0 0 1 0.0 2 0 2 28.6 0 0 2 0.0
DCIS 1 0 0 0 0.0 1 0 0 100.0 1 0 0 100.0
Prostate 75 0 0 6 0.0 6 1 11 10.9 0 0 11 0.0
Adenoca 75 0 0 6 0.0 6 1 11 10.9 0 0 11 0.0
Lung 75 10 20 16 50.8 10 23 7 48.5 7 11 9 27.3
Adenoca 32 2 2 3 13.8 3 0 3 10.3 0 0 3 0.0
PDC 4 0 1 1 33.3 1 0 1 33.3 0 0 1 0.0
SCC 39 8 17 12 92.6 4 23 3 75.0 7 11 5 52.9
Colon 75 0 1 4 1.4 2 1 13 4.8 0 0 14 0.0
Adenoca 66 0 1 3 1.6 2 1 13 5.7 0 0 13 0.0
Liver met 1 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0
Muc adenoca 6 0 0 1 0.0 0 0 0 0.0 0 0 0 0.0
Tub adeno 2 0 0 0 0.0 0 0 0 0.0 0 0 1 0.0
Ovary 50 5 0 5 11.1 6 6 6 27.3 4 0 5 8.9
CCC 8 0 0 1 0.0 0 1 1 14.3 0 0 1 0.0
Endomet 5 1 0 1 25.0 0 0 2 0.0 0 0 1 0.0
Muc adenoca 3 0 0 0 0.0 0 0 1 0.0 0 0 1 0.0
Serous pap 34 4 0 3 12.9 6 5 2 34.4 4 0 2 12.5
Melanoma 25 2 0 1 8.3 1 0 2 4.3 0 0 0 0.0
Primary 20 2 0 0 10.0 0 0 0 0.0 0 0 0 0.0
Metastatic 5 0 0 1 0.0 1 0 2 33.3 0 0 0 0.0
CNS 25 2 1 0 12.0 0 0 2 0.0 0 0 3 0.0
Glioblastoma 25 2 1 0 12.0 0 0 2 0.0 0 0 3 0.0
Total 400 24 23 39 13.0 36 34 53 20.2 14 13 55 7.8
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Fig. 2 Tissue microarray samples of a squamous cell carcinoma of
the lung (A, C, E) and an invasive ductal carcinoma of the breast
(B, D, F) showing expression of p63 (A, B), CK 5/6 (C, D) and CK
14 (E, F). (Streptavidin-biotin-peroxidase/diaminobenzidine; orig-
inal magnification 100 A, C, D, E, F; 400 B)
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Cytokeratin 5/6
Normal tissue samples
CK 5/6 was consistently expressed on the cytoplasm of
basal cells of esophageal stratified squamous epithelium
and pseudostratified bronchial epithelium; a variable
proportion of transitional epithelial cells of the bladder
was decorated as well. Myoepithelial cells of the breast
and sweat glands, basal cells of prostate acini, and
occasional cells lining pancreatic acini (Fig. 1B) showed
consistent expression of CK 5/6. Noteworthy, no immu-
noreactivity was observed in luminal cells of these glands.
A faint expression in hepatocytes, adrenocortical cells and
gastric parietal cells was also observed. No other epithe-
lial, mesenchymal, lymphoid or neural cell expressed
these CKs (Table 1).
Neoplasms
CK 5/6 consistently decorated squamous cell carcinomas
of the lung (75.0%, n=27) (Fig. 2C); conversely, only
10.3% of primary adenocarcinomas of the lung showed
CK 5/6 positivity. In breast carcinoma samples, CK 5/6
expression was observed in 20.0% of ductal carcinomas
(n=11) (Fig. 2D), 28.6% of lobular carcinomas (n=2), and
in the DCIS analyzed herein. Ovarian tumors showed a
differential expression of CK 5/6; whereas 34.4% of
serous papillary carcinomas of the ovary (n=11) and
14.3% of clear cell carcinomas (n=1) expressed CKs 5/6,
endometrioid (n=3) and mucinous (n=2) adenocarcinomas
were negative. Up to 10% of prostatic carcinomas (n=7)
and 5% of colonic carcinomas also showed CK 5/6
immunoreactivity. Tubular adenomas (n=2) showed no
immunoreactivity for this marker. Interestingly, non-
neoplastic breast ducts and prostate acini with CK 5/6
positive basal cells (admixed with breast and prostate
carcinomas) were depicted (Table 2).
No non-epithelial neoplasm showed any immunoex-
pression of CK 5/6 except a case of metastatic malignant
melanoma in which ~5% of the neoplastic cells showed a
faint paranuclear staining.
Cytokeratin 14
Normal tissue samples
The distribution of CK 14 was very similar to CK 5/6 but
for the lack of CK 14-positive cells in pancreatic acini
evaluated herein (Table 1). No immunoreactivity in
adrenocortical, hepatic or gastric epithelial cells was
observed. No mesenchymal, lymphoid or neural cell
stained with this antibody.
Neoplasms
CK 14 expression was observed in 52.9% of lung
squamous cell carcinomas (n=18) (Fig. 2E) and in no
lung adenocarcinomas. In the breast, 7.4% of invasive
ductal carcinomas (n=4) (Fig. 2F) and the DCIS expressed
CK 14, whereas all seven cases of lobular carcinomas
were negative for this intermediate filament. CK 14 also
decorated 12.5% of serous papillary carcinomas (n=4).
All other adenocarcinomas were consistently negative.
Normal breast ducts and prostate acini with CK 14 + cells
(admixed with breast and prostate carcinomas) were
observed. No CK 14 expression was detected in non-
epithelial neoplasms (Table 2).
Double immunostaining results
In salivary glands, p63 consistently decorated basal cells
of the excretory and striated ducts, as well as myoepithe-
lial cells of intercalated ducts and serous acini. A slightly
lower number of p63-positive cells was observed in
seromucinous or mucinous acini. CK 5/6 and CK 14 were
consistently expressed in myoepithelial cells of interca-
lated, striated and excretory ducts and in all types of acini.
Noteworthy, some luminal cells showed immunoreactiv-
ity for both CK 5/6 and CK 14. Interestingly, basal cells
of the ductal system (Fig. 3A and inset) and myoepithelial
cells of the acini (Fig. 3B) frequently showed concurrent
expression of p63/CK 5/6 and p63/CK 14.
In stratified squamous epithelia, we observed that p63
consistently stained basal cells and a variable proportion
of suprabasal cells, but almost no granular or fully
differentiated keratinocytes. CK 5/6 showed a similar
distribution. CK 14 strongly decorated the basal cell layer,
but was also expressed in suprabasal and fully differen-
tiated keratinocytes. Double immunostainings demonstra-
ted concurrent expression of p63/CK 5/6 and p63/CK 14
(Fig. 3C) in basal cells and in some suprabasal cells.
Sebaceous glands showed a peculiar distribution of CK 14
and p63; while p63 decorated basal cells of the sebaceous
glands, CK 14 preferentially stained fully differentiated
sebocytes (Fig. 3C and inset). No sebaceous glands were
observed in the sections double-stained for CK 5/6 and
p63. In breast lobules, concurrent expression of CK 5/6
and p63 (Fig. 3D), as well as CK 14 and p63 was
observed. Occasionally, scattered luminal cells of lobules
and ducts were decorated by CK 5/6. No immunoreac-
tivity for p63 or CK 14 was observed in luminal cells.
Statistical analysis
Squamous cell carcinomas expressed p63 (P<0.001), CK
5/6 (P<0.001) and CK 14 (P<0.001) more frequently than
adenocarcinomas of any site. Also, co-expression of p63/
CK 5/6, p63/CK 14, CK 5/6/CK 14, p63/CK 5/6/CK 14 in
matched samples was also more frequently observed in
squamous cell carcinomas than in adenocarcinomas
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Fig. 3 A p63 (dark-brown)/CK 14 (red) double immunostaining
showing concurrent expression of p63 and CK 14 in basal cells of
excretory ducts. Inset High-power magnification of excretory duct
epithelial cells. Note that only basal cells co-express p63 and CK
14. B Intercalated ducts and acini showing co-expression of p63
(dark-brown) and CK 5/6 (red) in basal and myoepithelial cells,
respectively. Inset Myoepithelial cells of serous acini concurrently
stained with p63 (dark-brown) and CK 14 (red). C Medium power
magnification of the skin stained for p63 (dark-brown) and CK 14
(red). Note the co-expression of p63 and CK 14 in epidermal basal
cells and the differential expression of these markers in basal cells
of the sebaceous glands and mature sebocytes. Inset High-power
magnification of a sebaceous gland. Note that p63 stained basal
cells, whereas fully differentiated sebocytes were decorated by CK
14. D Breast lobule showing concurrent expression of p63 (dark-
brown) and CK 5/6 (red) in basal/myoepithelial cells. [Streptavidin-
biotin-peroxidase-diaminobenzidine (DAB)/alkaline phosphatase
anti-alkaline phosphatase (APAAP)-fast red; original magnification
100 A, C; 400 A inset, B, B inset, D]
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(P<0.001, for all tests). Interestingly, p63 expression
showed a statistically significant association with CKs 5/6
and CK 14 expression, irrespective of the histological
type (squamous cell carcinoma or adenocarcinoma) of the
neoplasm (P<0.001, for both tests).
In breast carcinomas, no statistical association between
p63, CK 5/6 and CK 14 expression with the histological
type (invasive ductal carcinoma vs invasive lobular
carcinoma) was observed (P>0.9999, P=0.6304, and
P>0.9999, respectively). Matched tumor samples that
expressed p63 also expressed CK 5/6 (P=0.0002), all
tumors that expressed CK 14 also expressed CK 5/6
(P=0.0016) and a significant correlation between p63 and
CK 14 expression (P=0.0463) was found.
All cases of prostatic carcinomas were usual acinar
carcinomas. As the Gleason grade of the whole section of
these neoplasms was not provided in the TARP-4
database, we restricted the statistical analysis to the
putative co-expression of p63, CK 5/6 and CK 14 in
prostate adenocarcinoma matched samples. As no prostate
carcinoma analyzed herein expressed p63 or CK 14, no
statistical association was found in these neoplasms.
Concerning lung neoplasms, p63, CK 5/6 and CK 14
were more frequently expressed in squamous cell carci-
nomas than in adenocarcinomas or poorly differentiated
carcinomas (P<0.0001, all tests). Also, a significant
concordant expression of p63 and CK 5/6, p63 and CK
14, CK 5/6 and CK 14 in matched samples was found
(P<0.0001, all tests). When squamous cell and poorly
differentiated carcinomas were excluded, no statistical
association between p63, CK 5/6 and CK 14 expression
was found.
In colonic carcinomas, no statistical difference was
observed between the expression of p63 (P>0.9999) and
CKs 5/6 (P>0.9999) in glandular and mucinous adeno-
carcinomas. No colonic adenocarcinoma expressed CK
14. No statistical correlation was observed between the
expression of p63 and CK 14 in matched samples of these
neoplasms (P>0.9999).
In ovarian neoplasms, no association was found
between the histological type and the expression of p63,
CK 5/6 or CK 14 (P=0.5455, P=0.3499, P=0.6185). No
statistical correlation was observed between the expres-
sion of p63 and CK 5/6 (P=0.6077), p63 and CK 14
(P=0.3941), and CK 5/6 and CK 14 (P=0.2967) in
matched samples.
Discussion
Several studies have reported that DN-p63 isoforms are
consistently expressed in the nuclei of basal cells of
multilayered epithelia, including skin (epidermis and
sebaceous glands), cervical and vaginal mucosa, urothe-
lium, respiratory tract, and prostate, in myoepithelial and
basal cells of the breast and sweat glands, as well as in
cytotrophoblast of human placenta [1, 5, 10, 11, 12, 22,
24, 27, 30, 31, 32, 33, 34, 35, 36, 37, 39, 43, 47]. Analysis
of p63/ mice demonstrated that these mice present with
truncated limbs and have no hair follicles, teeth, mam-
mary, lachrymal or salivary glands [22, 24, 47]. More-
over, squamous epithelia of p63/ mice (i.e., squamous
epithelia of skin and tongue) failed to develop the
spinosum, granulosum and stratum corneum and to
correctly express CK 5 and CK 14 [22, 24, 47]. We
demonstrated that in salivary glands, p63 has a preferen-
tial expression in basal/myoepithelial cells of the inter-
calated, striated and excretory ducts, as well as in
myoepithelial cells of serous acini. A smaller proportion
of p63 positive myoepithelial cells was observed in
mucinous and seromucinous acini when compared with
parotid gland serous acini.
It has been demonstrated that anti-p63 antibodies
decorate the majority of squamous cell carcinomas [5, 11,
12, 19, 32, 36], basal cell carcinomas of the skin [11, 36],
transitional cell carcinomas [11, 19, 32], and tumors with
myoepithelial differentiation of the breast [32, 33, 38, 45]
and lungs [30]. Our study confirmed and expanded the
results of previously published studies that have demon-
strated p63 expression in almost all squamous cell
carcinomas [5, 11, 12, 14, 19, 30, 31, 43] and in a minor
proportion of ductal carcinomas of breast (4.6–11%) [1,
27]. Also, we observed that some serous and endometri-
oid carcinomas of the ovary and rare adenocarcinomas of
the colon express this marker.
Developmental analysis of p63 knockout mice has
demonstrated that the expression of CK 5 and CK 14 is
somehow controlled by p63 [22, 24, 47]. This is not
striking, as in vitro studies using transformed human
keratinocytes have shown that p63 is a nuclear transcrip-
tion factor that triggers the expression of keratinocytic
differentiation markers (i.e., involucrin and loricrin) [10,
22]. Conversely, when terminal differentiation is achieved
or triggered by other mechanisms, such as high calcium
exposure, there is a downregulation of all p63 isoforms
[10]. These data are in accordance with previous publi-
cations showing that p63 is expressed in squamous cell
carcinomas [5, 11, 12, 14, 19, 31]; however, terminally
differentiated cells, such as those observed in the center of
squamous pearls, are negative for this marker [36].
In the present study, we demonstrated a concurrent
expression of p63, CK 5/6 and CK 14 in 6.54% of human
carcinoma matched samples (18 of 275 carcinomas in
which all three samples from each neoplasm could be
unequivocally evaluated and none of them were necrotic,
fragmented or lost during immunohistochemical staining).
In adenocarcinomas, this triple concurrent expression in
matched samples was only observed in two invasive
ductal carcinomas of the breast. All the other 16 cases
were lung squamous cell carcinomas (25 of the 39
squamous cell carcinoma samples were unequivocally
evaluated for all markers and none of them were necrotic,
fragmented or lost during immunohistochemical proce-
dure). Our findings suggest that these markers may be
reliably used for the diagnosis of squamous cell carcino-
mas and also indicate that some breast carcinomas co-
express these markers.
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It has been described that up to 18% of breast
carcinomas may show a partial or complete basal/
myoepithelial phenotype [17, 18, 21]. Our double immu-
nohistochemical preparations demonstrated concurrent
expression of p63 and CK 5/6, as well as p63 and CK
14 in a subset of basal cells of breast lobules and ducts.
Also, we have already described a concurrent expression
of p63, p-cadherin, maspin, alpha smooth muscle actin ,
and CK 14 in a subset of metaplastic carcinomas of the
breast (tumors with putative basal/myoepithelial differ-
entiation) [37]. In the present study, 2 of 56 (3.57%)
invasive breast carcinomas samples that were unequivo-
cally evaluated for p63, CK 5/6 and CK 14 co-expressed
all of these markers, reiterating that a subset of breast
carcinomas may show a basal/myoepithelial phenotype
[17, 18, 21].
Multi-tumor TMAs have previously been used to
screen different tumor types for molecular alterations of
interest [3, 11, 15, 16, 20, 25, 41, 48]. We described
herein another application of multi-tumor TMAs: to
screen the distribution of immunohistochemical markers
used for diagnostic purposes in a plethora of tumor types.
The results of TMAs composed of a single 0.6-mm core
of each tumor are disputable; while some authors have
demonstrated that results from this sort of array have
demonstrated 97–98% concordance with results observed
in whole tissue sections for estrogen receptor, progester-
one receptor and c-erbB-2 [48], others have claimed that
arrays composed of a single 0.6 mm core would not cover
and represent the heterogeneity of human neoplasms [16].
This issue is even more important regarding markers that
are usually focally expressed in selected types of human
neoplasms, such as p63 and basal keratins in breast
carcinomas [1, 41]. Recently, validation studies of TMAs
have demonstrated that even for heterogeneously ex-
pressed markers, one single core can match the staining
pattern of an entire section more than 90% of the time and
that full section cut-off values may also be applied when
scoring TMAs [4, 15, 48]. Although we have not
compared our TMA data with whole histological sections
of the same tumors, our results are in accordance with
previously reported series on p63 [1, 5, 12, 14, 18, 19, 27,
29, 31, 36, 43, 44, 47], CKs 5/6 [2, 6, 9, 13, 19, 28, 42]
and CK 14 [7, 8, 13] distribution (Table 3).
In conclusion, we described the expression of p63,
CKs 5/6 and CK 14 in 350 carcinomas, 25 malignant
melanomas, and 25 glioblastomas using serial sections of
TARP-4 multi-tumor TMA. Regardless of the small-sized
samples included in the TMA, our results are in accor-
dance with previous studies performed on whole histo-
logical sections [1, 2, 5, 6, 7, 8, 9, 12, 13, 14, 18, 19, 27,
28, 29, 31, 36, 42, 43, 44, 46] and showed only minor
discrepancy with a similar study that was also performed
on TMAs [11], suggesting that TMAs can be used to
describe the distribution of antibodies that might be used
as diagnostic markers. Moreover, our results also corrob-
orate that p63, CKs 5/6 and CK 14 may be used as adjunct
antibodies for the pathologic recognition of squamous cell
carcinomas [6, 7, 8, 11, 19, 31, 47]. In addition, we also
demonstrated that a subset of breast carcinomas express
these markers [1, 17, 18, 32, 33, 37], and that this might
reflect a basal or an intermediary phenotype [18, 21],
despite their unremarkable morphology.
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